Wednesday, June 19, 2013

Stocks DD Opines on Anacor: An interesting speculative long term value play


Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article


Anacor pharma IR preso at Deutsche Bank Conf

-> http://www.media-server.com/m/p/o6med9nj

-> http://www.scribd.com/doc/149510844/Anacor-Investor-Presentation-June-2013-Compatibility-Mode

1. They have cash at least until launch next year
2. 1 interesting pre-NDA asset (onychomycosis) and another more interesting phase 3 asset(atopic dermatitis). Phase 3 to start early next year. There are good market comparables which seem to suggest the 2 products together could garner $300m in peak sales conservatively. Read company's IR presentation for details and Seeking Alpha contributors. SA link
3. Insider ownership very high at 46%. The company was founded >10 years ago.
4. Their market cap is <$209m
5. CFO purchased approx 43k shares at ~$5.2 in the open market this week.
6. Share price of $5.18 is below their recent secondary offering of $6.39.
7. They may be awarded a potential monetary settlement with Valeant in September after their arbitration hearing. If they win , they could get damages up to $215m in which case they will likely have no need to dilute in future. I will be studying the merits of this case and make another post.

Keep in mind, this is a speculative play.

No comments:

Post a Comment